CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

This new treatment could help bring relief for millions of Americans struggling with depression. The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression. The drug, SPRAVATO, is made by Johnson & Johnson and was first approved in 2019 for adults ...